Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Recruiting now

Conditions studied: Breast Carcinoma

In brief

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.

Key facts

Study ID

NCT02610413

Run by

National Cancer Institute (NCI)

People needed

354

Starts

2014-03-25

Expected to finish

2100-01-01

Last updated by the study team

2026-03-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• European American patients with deoxyribonucleic acid (DNA) available and designated case or control
• Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab
• Patients who did not develop hypertension following a full course of treatment with bevacizumab

Where it is running

• Eastern Cooperative Oncology Group — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.